New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 125ug;   - aerosol inhaler, metered dose - 125 mcg/dose - active: fluticasone propionate 125ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 250ug;   - aerosol inhaler, metered dose - 250 mcg/dose - active: fluticasone propionate 250ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 100ug;  ;   - powder for inhalation - 100 mcg - active: fluticasone propionate 100ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 250ug;  ;   - powder for inhalation - 250 mcg - active: fluticasone propionate 250ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 50ug;  ;   - powder for inhalation - 50 mcg - active: fluticasone propionate 50ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 500ug;  ;   - powder for inhalation - 500 mcg - active: fluticasone propionate 500ug     excipient: lactose monohydrate - adults: prophylactic management in: · mild asthma (pef values greater than 80% predicted at baseline with less than 20% variability): patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. · moderate asthma (pef values 60-80% predicted at baseline with 20-30% variability): patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. · severe asthma (pef values less than 60% predicted at baseline with greater than 30% variability): patients with severe chronic asthma. on introduction of inhaled fluticasone propionate many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. children: any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 50ug;   - aerosol inhaler, metered dose - 50 mcg/dose - active: fluticasone propionate 50ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hydrocortisone 1% - topical cream - 1 % - active: hydrocortisone 1%

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - naratriptan hydrochloride 2.78mg equivalent to 2.5 mg naratriptan;   - film coated tablet - 2.5 mg - active: naratriptan hydrochloride 2.78mg equivalent to 2.5 mg naratriptan   excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green as opadry green oy-s-21027 purified water - the acute treatment of migraine attacks with or without aura.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zanamivir 5mg (micronised);   - powder for inhalation - 5 mg - active: zanamivir 5mg (micronised)   excipient: lactose monohydrate - treatment of influenza: relenza is indicated for treatment of both influenza a and b in adults and children (5 years or older) who present with symptoms typical of influenza when influenza is circulating in the community. prophylaxis of influenza: vaccination remains the primary method of preventing and controlling influenza. relenza is indicated for prophylaxis of influenza a and b in adults and children (5 years or older) to reduce transmission among individuals in households with an infected person. relenza is indicated for prophylaxis of influenza a and b during community outbreaks only in circumstances where such prophylaxis is justified (such as when vaccine that antigenically matches circulating influenza is not available or there is a pandemic). it is not recommended for routine prophylaxis against influenza infection.